Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma(RCC)

PHASE2UnknownINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
AnlotinibRCC
Interventions
DRUG

Anlotinib

Anlotinib p.o. qd

DRUG

Sunitinib maleate

Sunitinib 50 mg p.o. qd

Trial Locations (15)

100005

Peking Union Medical College Hospital, Beijing

100021

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

110000

China General Hospital of Shenyang Military Region, Shenyang

110042

Liaoning Province Tumor Hospital, Shenyang

132000

Jilin Cancer Hospital, Changchun

150000

Harbin medical university affiliated tumor hospital, Haerbin

200000

Cancer Hospital of Fudan University, Shanghai

210000

The 81st Hospital of Chinese PLA, Nanjing

250012

Qilu Hospital,Shandong University, Jinan

300000

Tianjin Medical University Cancer Hospital, Tianjin

404100

Chongqing Cancer Hospital, Chongqing

510000

Sun Yat-Sen University Cancer Center, Guangzhou

530021

Guangxi medical university affiliated tumor hospital, Nanning

610041

West China Hospital,Sichuan University, Chengdu

730050

Gansu Province Tumor Hospital, Lanzhou

All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY